ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Cardiol Therapeutics Inc Class A (CRDL.TO)
Cardiol Therapeutics Inc Class A stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Toronto Stock Exchange · Canada
CA$1.62▲ +1.25%
Prices as of Oct 27, 2026 · CAD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Cardiol Therapeutics Inc Class A in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Cardiol Therapeutics Inc Class A
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Cardiol Therapeutics Inc Class A a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CA$1.41 and CA$1.81; in 9 out of 10, between CA$1.13 and CA$2.25. Estimated annual volatility is 71%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- CA$193M
- Market cap (USD)
- $137M
- 52-week high
- CA$3.23
- 52-week low
- CA$1.23
- Operating margin
- 0.0%
- Net margin
- 0.0%
- Beta
- 0.73
What this means
ATLAS does not publish a fair value for CRDL.TO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CRDL.TO has traded between CA$1.23 and CA$3.23. Today it is 49.9% below that high and 32% above its low.
Its beta is 0.73: it tends to move less than the market.
About the company
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Want to see everything about Cardiol Therapeutics Inc Class A?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Cardiol Therapeutics Inc Class A do?
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
What is the chance CRDL.TO goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, CRDL.TO ends the month between CA$1.41 and CA$1.81.
How big is Cardiol Therapeutics Inc Class A and what is its P/E ratio?
Cardiol Therapeutics Inc Class A's market capitalization is CA$193M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is CRDL.TO?
ATLAS estimates annual volatility at 71%. In a typical month, half of the outcomes end between CA$1.41 and CA$1.81.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer